Justine Nuytens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Justine Nuytens has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Jasper Anckaert
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
10 shared publications - Jo Vandesompele
Cancer Research Institute Ghent, Ghent, Belgium
10 shared publications - Pieter Mestdagh
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
9 shared publications - Eveline Vanden Eynde
OncoRNALab, Cancer Research Institute Ghent (CRIG), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
7 shared publications - Nurten Yigit
OncoRNALab, Cancer Research Institute Ghent (CRIG), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
6 shared publications - Annelien Morlion
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
4 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Background Circulating nucleic acids in blood plasma form an attractive, minimally invasive resource to study human health and disease. In this study, we aimed to identify cell-free RNA alterations that can distinguish cancer patients from cancer-free individuals. Methods We first performed mRNA capture sequencing on 266 blood plasma samples from cancer patients and controls, including a discovery set of 208 donors across 25 cancer types and a replication set of 58 donors across three cancer types. We first conducted group-level comparisons and then compared individual patient profiles to a reference control population in a one-versus-many approach. This approach was further evaluated in independent cohorts: a prostate cancer plasma cohort (n = 180), a non-malignant disease plasma cohort (n = 125), a lymphoma plasma cohort (n = 65), and a bladder cancer urine cohort (n = 24), each including both patients and controls. Results Here we show that cancer patients exhibit both cancer type-specific and general cell-free RNA alterations. However, differentially abundant RNAs vary widely among patients and across cohorts, hampering robust biomarker identification. By comparing individual patient profiles to control populations, we identify so-called biomarker tail genes, which strongly deviate from controls. The number of these genes per sample distinguishes cancer patients from control samples. Independent cohorts also confirm the potential of this approach. Conclusions Our findings demonstrate substantial heterogeneity in cell-free RNA alterations among cancer patients and propose that patient-specific changes can be exploited for classification.
- 7 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessPatient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Background Circulating nucleic acids in blood plasma form an attractive, minimally invasive resource to study human health and disease. In this study, we aimed to identify cell-free RNA alterations that can distinguish cancer patients from cancer-free individuals. Methods We first performed mRNA capture sequencing on 266 blood plasma samples from cancer patients and controls, including a discovery set of 208 donors across 25 cancer types and a replication set of 58 donors across three cancer types. We first conducted group-level comparisons and then compared individual patient profiles to a reference control population in a one-versus-many approach. This approach was further evaluated in independent cohorts: a prostate cancer plasma cohort (n = 180), a non-malignant disease plasma cohort (n = 125), a lymphoma plasma cohort (n = 65), and a bladder cancer urine cohort (n = 24), each including both patients and controls. Results Here we show that cancer patients exhibit both cancer type-specific and general cell-free RNA alterations. However, differentially abundant RNAs vary widely among patients and across cohorts, hampering robust biomarker identification. By comparing individual patient profiles to control populations, we identify so-called biomarker tail genes, which strongly deviate from controls. The number of these genes per sample distinguishes cancer patients from control samples. Independent cohorts also confirm the potential of this approach. Conclusions Our findings demonstrate substantial heterogeneity in cell-free RNA alterations among cancer patients and propose that patient-specific changes can be exploited for classification.
- Open Access
- 17 January 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (2) , 448
Author Correction: Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision
- 17 January 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (2) , 448
Open AccessAuthor Correction: Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision
- Open Access
- 22 July 2024
- Published by Springer Nature in Research Square
Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling: A large-scale pre-analytical variable performance evaluation
Using blood-based extracellular RNA (circulating cell-free RNA; exRNA) as a clinical biomarker requires validated procedures for sample collection and processing and RNA quantification. No study to date has systematically tested pre-analytical variables affecting transcriptome-wide exRNA analysis. We evaluated and compared ten blood collection tubes, three time intervals between blood draw and blood processing, and eight RNA purification methods using the supplier-specified minimal and maximal biofluid input volumes. The impact on deep transcriptome profiling of both microRNAs and messenger RNAs in blood plasma or serum was separately assessed for each pre-analytical variable and for interactions among a selected pre-analytical variable set, resulting in 456 complete extracellular transcriptomes. The processing and analysis workflow was controlled using 189 synthetic spike-in RNA molecules. In blood collection tube comparisons, manufacturer-designated preservation tubes did not stabilize exRNA well, causing variations in RNA concentration and number of detected genes over time, together with increased replicate variability. We also document large performance differences in RNA purification methods, affecting detected gene number, replicate variability and observed transcriptome complexity, and demonstrate technical interactions between certain blood collection tubes, purification methods and time intervals. Our results are comprehensively summarized in 11 analytical performance metrics that enable an informed selection of the best sample processing workflow for a given experiment. We provide robust quality control metrics for exRNA quantification methods with validated standard operating procedures (SOPs), and put forward recommendations for both users and manufacturers of RNA purification methods and blood collection tubes, collectively, essential groundwork for future exRNA-based precision medicine applications.
- 22 July 2024
- Published by Springer Nature in Research Square
Open AccessBlood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling: A large-scale pre-analytical variable performance evaluation
Using blood-based extracellular RNA (circulating cell-free RNA; exRNA) as a clinical biomarker requires validated procedures for sample collection and processing and RNA quantification. No study to date has systematically tested pre-analytical variables affecting transcriptome-wide exRNA analysis. We evaluated and compared ten blood collection tubes, three time intervals between blood draw and blood processing, and eight RNA purification methods using the supplier-specified minimal and maximal biofluid input volumes. The impact on deep transcriptome profiling of both microRNAs and messenger RNAs in blood plasma or serum was separately assessed for each pre-analytical variable and for interactions among a selected pre-analytical variable set, resulting in 456 complete extracellular transcriptomes. The processing and analysis workflow was controlled using 189 synthetic spike-in RNA molecules. In blood collection tube comparisons, manufacturer-designated preservation tubes did not stabilize exRNA well, causing variations in RNA concentration and number of detected genes over time, together with increased replicate variability. We also document large performance differences in RNA purification methods, affecting detected gene number, replicate variability and observed transcriptome complexity, and demonstrate technical interactions between certain blood collection tubes, purification methods and time intervals. Our results are comprehensively summarized in 11 analytical performance metrics that enable an informed selection of the best sample processing workflow for a given experiment. We provide robust quality control metrics for exRNA quantification methods with validated standard operating procedures (SOPs), and put forward recommendations for both users and manufacturers of RNA purification methods and blood collection tubes, collectively, essential groundwork for future exRNA-based precision medicine applications.
- 13 July 2023
- Published by Springer Nature in Nature Methods
- Vol. 20 (8) , 1159-1169
Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision
The detection of circular RNA molecules (circRNAs) is typically based on short-read RNA sequencing data processed using computational tools. Numerous such tools have been developed, but a systematic comparison with orthogonal validation is missing. Here, we set up a circRNA detection tool benchmarking study, in which 16 tools detected more than 315,000 unique circRNAs in three deeply sequenced human cell types. Next, 1,516 predicted circRNAs were validated using three orthogonal methods. Generally, tool-specific precision is high and similar (median of 98.8%, 96.3% and 95.5% for qPCR, RNase R and amplicon sequencing, respectively) whereas the sensitivity and number of predicted circRNAs (ranging from 1,372 to 58,032) are the most significant differentiators. Of note, precision values are lower when evaluating low-abundance circRNAs. We also show that the tools can be used complementarily to increase detection sensitivity. Finally, we offer recommendations for future circRNA detection and validation.
- 13 July 2023
- Published by Springer Nature in Nature Methods
- Vol. 20 (8) , 1159-1169
Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision
The detection of circular RNA molecules (circRNAs) is typically based on short-read RNA sequencing data processed using computational tools. Numerous such tools have been developed, but a systematic comparison with orthogonal validation is missing. Here, we set up a circRNA detection tool benchmarking study, in which 16 tools detected more than 315,000 unique circRNAs in three deeply sequenced human cell types. Next, 1,516 predicted circRNAs were validated using three orthogonal methods. Generally, tool-specific precision is high and similar (median of 98.8%, 96.3% and 95.5% for qPCR, RNase R and amplicon sequencing, respectively) whereas the sensitivity and number of predicted circRNAs (ranging from 1,372 to 58,032) are the most significant differentiators. Of note, precision values are lower when evaluating low-abundance circRNAs. We also show that the tools can be used complementarily to increase detection sensitivity. Finally, we offer recommendations for future circRNA detection and validation.
- Open Access
Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Circulating nucleic acids in blood plasma form an attractive resource to study human health and disease. Here, we applied mRNA capture sequencing of blood plasma cell-free RNA from 266 cancer patients and cancer-free controls (discovery n = 208, 25 cancer types; replication n = 58, 3 types). We observed cancer type-specific as well as pan-cancer alterations in cell-free transcriptomes compared to controls. Differentially abundant RNAs were heterogenous among patients and among cohorts, hampering identification of robust cancer biomarkers. Therefore, we developed a novel method that compares each individual cancer patient to a reference control population to identify so-called biomarker tail genes. The number of biomarker tail genes in a sample enables distinguishing an individual cancer patient from controls. The potential of this novel approach was confirmed in additional cohorts of 65 plasma donors (2 lymphoma types) and 24 urine donors (bladder cancer). Together, our findings demonstrate heterogeneity in cell-free RNA alterations among cancer patients and propose that case-specific alterations can be exploited for classification purposes.
Open AccessPatient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Circulating nucleic acids in blood plasma form an attractive resource to study human health and disease. Here, we applied mRNA capture sequencing of blood plasma cell-free RNA from 266 cancer patients and cancer-free controls (discovery n = 208, 25 cancer types; replication n = 58, 3 types). We observed cancer type-specific as well as pan-cancer alterations in cell-free transcriptomes compared to controls. Differentially abundant RNAs were heterogenous among patients and among cohorts, hampering identification of robust cancer biomarkers. Therefore, we developed a novel method that compares each individual cancer patient to a reference control population to identify so-called biomarker tail genes. The number of biomarker tail genes in a sample enables distinguishing an individual cancer patient from controls. The potential of this novel approach was confirmed in additional cohorts of 65 plasma donors (2 lymphoma types) and 24 urine donors (bladder cancer). Together, our findings demonstrate heterogeneity in cell-free RNA alterations among cancer patients and propose that case-specific alterations can be exploited for classification purposes.
- Open Access
- 15 November 2021
- Published by Springer Nature in Oncogene
- Vol. 41 (1) , 146
Correction to: The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
- 15 November 2021
- Published by Springer Nature in Oncogene
- Vol. 41 (1) , 146
Open AccessCorrection to: The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
- Open Access
mTOR inhibition enhances delivery and activity of antisense oligonucleotides in uveal melanoma cells
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Due to a lack of effective treatments, patients with metastatic disease have a median survival time of 6-12 months. We recently demonstrated that the SAMMSON long non-coding RNA (lncRNA) is essential for uveal melanoma cell survival and that antisense oligonucleotide (ASO)-mediated silencing of SAMMSON impaired cell viability and tumor growth in vitro and in vivo . By screening a library of 2911 clinical stage compounds, we identified the mTOR inhibitor GDC-0349 to synergize with SAMMSON inhibition in UM. Mechanistic studies revealed that mTOR inhibition enhanced uptake and reduced lysosomal accumulation of lipid complexed SAMMSON ASOs, improving SAMMSON knockdown and further decreasing UM cell viability. We found mTOR inhibition to also enhance target knockdown in other cancer cell lines as well as normal cells when combined with lipid nanoparticle complexed or encapsulated ASOs or small interfering RNAs (siRNAs). Our results are relevant to nucleic acid treatment in general and highlight the potential of mTOR inhibition to enhance ASO and siRNA mediated target knockdown.
Open AccessmTOR inhibition enhances delivery and activity of antisense oligonucleotides in uveal melanoma cells
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Due to a lack of effective treatments, patients with metastatic disease have a median survival time of 6-12 months. We recently demonstrated that the SAMMSON long non-coding RNA (lncRNA) is essential for uveal melanoma cell survival and that antisense oligonucleotide (ASO)-mediated silencing of SAMMSON impaired cell viability and tumor growth in vitro and in vivo . By screening a library of 2911 clinical stage compounds, we identified the mTOR inhibitor GDC-0349 to synergize with SAMMSON inhibition in UM. Mechanistic studies revealed that mTOR inhibition enhanced uptake and reduced lysosomal accumulation of lipid complexed SAMMSON ASOs, improving SAMMSON knockdown and further decreasing UM cell viability. We found mTOR inhibition to also enhance target knockdown in other cancer cell lines as well as normal cells when combined with lipid nanoparticle complexed or encapsulated ASOs or small interfering RNAs (siRNAs). Our results are relevant to nucleic acid treatment in general and highlight the potential of mTOR inhibition to enhance ASO and siRNA mediated target knockdown.
- Open Access
- 10 September 2021
- Published by Springer Nature in Oncogene
- Vol. 41 (1) , 15-25
The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
Long non-coding RNAs (lncRNAs) can exhibit cell-type and cancer-type specific expression profiles, making them highly attractive as therapeutic targets. Pan-cancer RNA sequencing data revealed broad expression of the SAMMSON lncRNA in uveal melanoma (UM), the most common primary intraocular malignancy in adults. Currently, there are no effective treatments for UM patients with metastatic disease, resulting in a median survival time of 6–12 months. We aimed to investigate the therapeutic potential of SAMMSON inhibition in UM. Antisense oligonucleotide (ASO)-mediated SAMMSON inhibition impaired the growth and viability of a genetically diverse panel of uveal melanoma cell lines. These effects were accompanied by an induction of apoptosis and were recapitulated in two uveal melanoma patient derived xenograft (PDX) models through subcutaneous ASO delivery. SAMMSON pulldown revealed several candidate interaction partners, including various proteins involved in mitochondrial translation. Consequently, inhibition of SAMMSON impaired global, mitochondrial and cytosolic protein translation levels and mitochondrial function in uveal melanoma cells. The present study demonstrates that SAMMSON expression is essential for uveal melanoma cell survival. ASO-mediated silencing of SAMMSON may provide an effective treatment strategy to treat primary and metastatic uveal melanoma patients.
- 10 September 2021
- Published by Springer Nature in Oncogene
- Vol. 41 (1) , 15-25
Open AccessThe long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
Long non-coding RNAs (lncRNAs) can exhibit cell-type and cancer-type specific expression profiles, making them highly attractive as therapeutic targets. Pan-cancer RNA sequencing data revealed broad expression of the SAMMSON lncRNA in uveal melanoma (UM), the most common primary intraocular malignancy in adults. Currently, there are no effective treatments for UM patients with metastatic disease, resulting in a median survival time of 6–12 months. We aimed to investigate the therapeutic potential of SAMMSON inhibition in UM. Antisense oligonucleotide (ASO)-mediated SAMMSON inhibition impaired the growth and viability of a genetically diverse panel of uveal melanoma cell lines. These effects were accompanied by an induction of apoptosis and were recapitulated in two uveal melanoma patient derived xenograft (PDX) models through subcutaneous ASO delivery. SAMMSON pulldown revealed several candidate interaction partners, including various proteins involved in mitochondrial translation. Consequently, inhibition of SAMMSON impaired global, mitochondrial and cytosolic protein translation levels and mitochondrial function in uveal melanoma cells. The present study demonstrates that SAMMSON expression is essential for uveal melanoma cell survival. ASO-mediated silencing of SAMMSON may provide an effective treatment strategy to treat primary and metastatic uveal melanoma patients.
- 28 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1467
Publisher Correction: The RNA Atlas expands the catalog of human non-coding RNAs
- 28 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1467
Publisher Correction: The RNA Atlas expands the catalog of human non-coding RNAs
- 17 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1453-1465
The RNA Atlas expands the catalog of human non-coding RNAs
Existing compendia of non-coding RNA (ncRNA) are incomplete, in part because they are derived almost exclusively from small and polyadenylated RNAs. Here we present a more comprehensive atlas of the human transcriptome, which includes small and polyA RNA as well as total RNA from 300 human tissues and cell lines. We report thousands of previously uncharacterized RNAs, increasing the number of documented ncRNAs by approximately 8%. To infer functional regulation by known and newly characterized ncRNAs, we exploited pre-mRNA abundance estimates from total RNA sequencing, revealing 316 microRNAs and 3,310 long non-coding RNAs with multiple lines of evidence for roles in regulating protein-coding genes and pathways. Our study both refines and expands the current catalog of human ncRNAs and their regulatory interactions. All data, analyses and results are available for download and interrogation in the R2 web portal, serving as a basis for future exploration of RNA biology and function.
- 17 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1453-1465
The RNA Atlas expands the catalog of human non-coding RNAs
Existing compendia of non-coding RNA (ncRNA) are incomplete, in part because they are derived almost exclusively from small and polyadenylated RNAs. Here we present a more comprehensive atlas of the human transcriptome, which includes small and polyA RNA as well as total RNA from 300 human tissues and cell lines. We report thousands of previously uncharacterized RNAs, increasing the number of documented ncRNAs by approximately 8%. To infer functional regulation by known and newly characterized ncRNAs, we exploited pre-mRNA abundance estimates from total RNA sequencing, revealing 316 microRNAs and 3,310 long non-coding RNAs with multiple lines of evidence for roles in regulating protein-coding genes and pathways. Our study both refines and expands the current catalog of human ncRNAs and their regulatory interactions. All data, analyses and results are available for download and interrogation in the R2 web portal, serving as a basis for future exploration of RNA biology and function.